Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(4):248-249; doi:10.1093/jnci/94.4.248
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Michalowski, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michalowski, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 4, 248-249, February 20, 2002
© 2002 Oxford University Press

NEWS

COX-2 Inhibitors: Cancer Trials Test New Uses for Pain Drug

Jennifer Michalowski

A drug that was originally approved for its anti-inflammatory properties has quickly become the focus of a broad range of cancer trials that aim to establish the drug’s effectiveness in preventing or treating nine different types of cancer.

By the time the U.S. Food and Drug Administration approved the COX-2 inhibitor celecoxib for polyp prevention in patients with familial adenomatous polyposis (FAP) in December 1999, clinical trials investigating the drug’s potential to help prevent colorectal cancer and three other cancers were already in progress. Today, experts are optimistic that the drug may prove useful for cancer treatment as well.

"Here we have a drug that was designed to . . . [Full Text of this Article]

Prevention Trials

Combination Therapies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
L. Y. Y. Fong, L. Zhang, Y. Jiang, and J. L. Farber
Dietary Zinc Modulation of COX-2 Expression and Lingual and Esophageal Carcinogenesis in Rats
J Natl Cancer Inst, January 5, 2005; 97(1): 40 - 50.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
W. E. Hardman
Omega-3 Fatty Acids to Augment Cancer Therapy
J. Nutr., November 1, 2002; 132(11): 3508S - 3512.
[Abstract] [Full Text] [PDF]